Dual PET/CT Imaging in Lung Cancer (DILUCE)

Odense University Hospital

Status

Unknown

Conditions

Lung Cancer

Treatments

Other: Dual FDG-PET/CT

Study type

Observational

Funder types

Other

Identifiers

NCT01539928

NMA 61 DILUCE

Details and patient eligibility

About

The purpose of this study is to compare conventional PET/CT scan performed 1 hour after injection of the radioactive tracer FDG (PET/CT[1]) with PET/CT performed after 3 hours (PET/CT[3]) in a group of patients with biopsy verified lung cancer or high suspicion of lung cancer after initial work-up (chest x-ray and CT of thorax/upper abdomen), who are potentially operable.

Full description

The investigators also want to:

To find the sensitivity, specificity and accuracy in PET/CT 1h and 3 h in the staging of lung cancer (N-/M-stage). Our gold standard is pathology, when not possible - follow-up (se Gold Standard 6.1.1)
To compare SUVmax with the expression of GLUT1 and G-6-Pase in tumors
To compare the expression of GLUT1 with the activity of G6Pase
To compare SUVmax, RI, tumor/liver ratio, GLUT1 and G-6-Pase with the occurrence of relapse within a year after curative surgery

Enrollment

216 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Cytologic/histologic-verified lung cancer or high suspicion of lung cancer after initial work up
Candidate to curative intended surgery after initial work up (usually chest x-ray, CT of chest/upper abdomen and if needed spirometry).

Exclusion criteria